Copyright
©The Author(s) 2023. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Hepatol. Jul 27, 2023; 15(7): 867-882
Published online Jul 27, 2023. doi: 10.4254/wjh.v15.i7.867
Published online Jul 27, 2023. doi: 10.4254/wjh.v15.i7.867
Gut microbiome and metabolic-associated fatty liver disease: Current status and potential applications
Gong-Jing Guo, Gastroenterology Department of The Second Affiliated Hospital, School of Medicine, The Chinese University of Hong Kong, Shenzhen & Longgang District People’s Hospital of Shenzhen, Shenzhen 518172, Guangdong Province, China
Fei Yao, Department of Science and Education, The Affiliated Brain Hospital of Guangzhou Medical University, Guangzhou 510370, Guangdong Province, China
Wei-Peng Lu, The First Clinical School, Guangzhou Medical University, Guangzhou 510120, Guangdong Province, China
Hao-Ming Xu, Department of Gastroenterology and Hepatology, Guangzhou First People's Hospital, School of Medicine, South China University of Technology, Guangzhou 510180, Guangdong Province, China
Author contributions: Guo GJ and Yao F performed the majority of the draft writing, revision of manuscript and prepared the references; Lu WP prepared the figures and table, coordinated the writing of the paper; Xu HM organized the interpretation of the data and revision of the article.
Supported by Guangzhou Planned Project of Science and Technology , No. 2023A04J0612 .
Conflict-of-interest statement: The authors declare that they have no competing interests.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Hao-Ming Xu, Doctor, MD, Doctor, Department of Gastroenterology and Hepatology, Guangzhou First People's Hospital, School of Medicine, South China University of Technology, No. 1 Panfu Road, Guangzhou 510180, Guangdong Province, China. haomingxu1992@126.com
Received: March 23, 2023
Peer-review started: March 23, 2023
First decision: May 14, 2023
Revised: June 11, 2023
Accepted: June 30, 2023
Article in press: June 30, 2023
Published online: July 27, 2023
Peer-review started: March 23, 2023
First decision: May 14, 2023
Revised: June 11, 2023
Accepted: June 30, 2023
Article in press: June 30, 2023
Published online: July 27, 2023
Core Tip
Core Tip: Metabolic-associated fatty liver disease (MAFLD) is a highly prevalent metabolic disease worldwide. In this review, we provide an overview of the current status and potential applications of the gut microbiota (GM) in MAFLD, focusing on key aspects such as bile acid circulation, energy metabolism, and microelement disorder, as well as signal pathways and GM metabolites implicated in MAFLD development and treatments, with a particular emphasis on targeting the microbiome.